Contact us
New Drug
HCB303
Innovative Protein Therapeutic
An innovative First-in-Class multi-target biologic developed based on the FBDB technology platform. Using the IgG antibody Fc region as the backbone, it incorporates protein molecules targeting three distinct pathways, providing multiple biological activities and the ability to simultaneously inhibit multiple signaling pathways.
HCB101
Innovative Protein Therapeutic
A best-in-class (BIC) oncology immunotherapy biologic, engineered as a 3.5th-generation SIRPα drug. HCB101 demonstrates an excellent safety profile and shows strong therapeutic potential against multiple solid tumors and non-Hodgkin’s lymphoma (NHL).
HCB301
Innovative Protein Therapeutic
An advanced tri-functional biologic representing only 1.6% of global biologics in development. HCB101 HCB301 is designed to simultaneously activate macrophages and T cells, reduce immunosuppression within the tumor microenvironment (TME), and demonstrates promising efficacy and safety in the treatment of multiple solid tumors.
HCB303
Innovative Protein Therapeutic
Next-Generation Tri-functional Immuno-Oncology Biologic
Primary Targets

CD47, PD-L1 & TME-related molecules
Targeting multiple solid tumors and non-Hodgkin’s lymphoma (NHL).

Currently in late preclinical development

Expected to enter the clinical stage soon.

Research Initiation
Biologics Optimization
Preclinical Studies
IND Application
Clinical Phase I
Clinical Phase II
Clinical Phase III
BLA / Market Approval
HCB101
Innovative Protein Therapeutic
A BIC immune-oncology biologic drug candidate.
Primary Target

CD47
Clinical trials are being conducted across multiple hospitals in Taiwan, the United States, and Mainland China, targeting various solid tumors and non-Hodgkin’s lymphoma (NHL).

Clinical Phase 1a

Monotherapy use.
High-dose administration confirmed safe by the Safety Review Committee (SRC).
Multiple cases of significant tumor shrinkage (PR, Partial Response) observed in treated patients.

Clinical Phase 1b/2 (Ongoing)

Combination therapy with standard of care (SOC).
Target indications include head and neck cancer, triple-negative breast cancer, gastric cancer, and colorectal cancer.

Research Initiation
Biologics Optimization
Preclinical Studies
IND Application
Clinical Phase I
Clinical Phase II
Clinical Phase III
BLA / Market Approval
HCB301
Innovative Protein Therapeutic
Next-Generation Tri-functional Immuno-Oncology Biologic
Primary Targets

CD47, PD-L1 & TME-related molecules
Targeting multiple solid tumors and non-Hodgkin’s lymphoma (NHL).

Clinical Phase 1a

Monotherapy use.
IND approvals obtained from both the U.S. FDA, Taiwan TFDA and China NMPA.
First patient enrolled and dosed.

Research Initiation
Biologics Optimization
Preclinical Studies
IND Application
Clinical Phase I
Clinical Phase II
Clinical Phase III
BLA / Market Approval